ReviewBritish journal of clinical pharmacology2014
Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders.
Review in British journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 69 citations in OpenAlex.
- Association of the Serum Folate and Total Calcium and Magnesium Levels Before Ovarian Stimulation With Outcomes of FreshFrontiers in endocrinology · 2022Trial
- Exploring rare coumarins biosynthesis by Gloeophyllum trabeum: an integrated computational genomics, molecular docking and spectroscopic approach.World journal of microbiology & biotechnology · 2026Article
- Discovery and optimization of a novel non-nitrocatechol COMT inhibitor for modulating levodopa metabolism.Journal of pharmaceutical analysis · 2026Article
- Evaluation of phytochemicals from Tamarindus indica as a potential catechol-O-methyltransferase (COMT) inhibitor: an in-silico approach for Parkinson's disease.Scientific reports · 2026Article
- Computer-aided design of caffeic acid derivatives: free radical scavenging activity and reaction force.Journal of molecular modeling · 2024Article
- Recent Progress in Synthetic and Natural Catechol-ACS omega · 2024Review
- Characterization of a unique catechol-O-methyltransferase as a molecular drug target in parasitic filarial nematodes.PLoS neglected tropical diseases · 2024Article
- Biosynthesis of Hesperetin, Homoeriodictyol, and Homohesperetin in a Transcriptomics-Driven Engineered Strain ofInternational journal of molecular sciences · 2024Article
- Rational Design of Multifunctional Ferulic Acid Derivatives Aimed for Alzheimer's and Parkinson's Diseases.Antioxidants (Basel, Switzerland) · 2023Article
- A large conserved family of small-molecule carboxyl methyltransferases identified from microorganisms.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Target Class Profiling of Small-Molecule Methyltransferases.ACS chemical biology · 2023Article
- Transcriptome Sequencing of the DiatomMarine drugs · 2023Article
- The Effects of Antioxidant Nutraceuticals on Cellular Sulfur Metabolism and Signaling.Antioxidants & redox signaling · 2023Review
- A Halogen-Atom Transfer (XAT)-Based Approach to Indole Synthesis Using Aryl Diazonium Salts and Alkyl Iodides.Organic letters · 2022Article
- Methyltransferases: Functions and Applications.Chembiochem : a European journal of chemical biology · 2022Review
- Discovery of Small Molecules as Membrane-Bound Catechol-Pharmaceuticals (Basel, Switzerland) · 2021Article
- Inhibition of catechol-Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Interaction of silver nanoparticles with catecholBiochemistry and biophysics reports · 2021Article
- Computational analysis of deleterious single nucleotide polymorphisms in catechol O-Methyltransferase conferring risk to post-traumatic stress disorder.Journal of psychiatric research · 2021Article
- Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catechol-O-methyltransferase (COMT) is of great importance in pharmacology because it catalyzes the metabolism (methylation) of endogenous and xenobiotic catechols. Moreover, inhibition of COMT is the drug target in the management of central nervous system (CNS) disorders such as Parkinson's disease due to its role in regulation of the dopamine level in the brain. The X-ray crystal structures for COMT have been available since 1994. The active sites for cofactor and substrate/inhibitor binding are well resolved to an atomic level, providing valuable insights into the catalytic mechanisms as well as the role of magnesium ions in catalysis. Determination of how the substrates/inhibitors bind to the protein leads to a structure-based approach that has resulted in potent and selective inhibitors. This review focuses on the design of two types of inhibitors (nitrocatechol-type and bisubstrate inhibitors) for COMT using the protein structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.